EMERGENCE OF VACCINE-DERIVED POLIOVIRUSES DURING EBOLA VIRUS DISEASE OUTBREAK IN GUINEA, 2014–2015

M.D. Fernandez-Garcia1, M. Majumdar2, O. Kebe1, A.D. Fall1, M. Kone2, M. Kande2, M. Dabo1, M.S. Sylla1, D. Sompare1, W. Howard4, O. Faye1, J. Martin1, K. Ndiaye1

1Institut Pasteur, Dakar, Senegal; 2National Institute for Biological Standards and Control, Potters Bar, United Kingdom; 3National Institute for Communicable Diseases, Johannesburg, South Africa

From December 2013 to May 2016, 3,351 laboratory-confirmed cases of EVD occurred in Guinea, resulting in 2,083 deaths and reaching a peak of 509 confirmed cases in October 2014. During this outbreak, 13 type 2 circulating vaccine-derived polioviruses (cVDPVs) were isolated from 6 polio patients and 7 healthy contacts. To clarify the genetic properties of cVDPVs and their emergence, we combined epidemiologic and virologic data for polio cases in Guinea.

Patients with paralytic poliomyelitis were identified through Guinea’s AFP surveillance system according to WHO guidelines. During September 2015–December 2016, additional fecal samples were collected from contacts of most AFP patients.

Polioviruses were isolated from fecal samples according to WHO standard procedures and subjected to intratypic differentiation by reverse transcription PCR targeting the VP1 region. Typing of non-polio enterovirus isolates was performed by RT-snPCR targeting part of the 3’-VP3 and the 5’-VP1 regions. Isolates with discordant intratypic differentiation results were sent to the National Institute for Communicable Diseases, Johannesburg, South Africa, for entire VP1 sequencing according to WHO guidelines.

To assess epidemiologic factors associated with the outbreak of Ebola Virus Disease (EBV), field investigations were conducted during December 17–28, 2015, in Siguiri and Kankan Prefectures, Guinea.

In September 2014, a case of laboratory-confirmed type 2 cVDPV infection was identified in Guinea (Siguiri Prefecture). During October 2014–March 2015, collection of fecal samples from AFP patients in Guinea was interrupted because of the outbreak of EVD. On September 4, 2015, type 2 cVDPV was isolated from a fecal sample of a child living in the Kankan region of Guinea. Subsequently, type 2 cVDPV isolates were recovered from 5 other AFP patients and 7 healthy contacts. The 7 healthy type 2 cVDPV-positive contacts were epidemiologically linked to 3 of the AFP case-patients. Most (12/13) poliovirus-positive case-patients were incompletely vaccinated children. All 13 type 2 cVDPV strains were isolated from persons in the Kankan region in eastern Guinea, most (12/13) persons were from Siguiri Prefecture. During the first semester of 2015, the coverage of routine OPV3 vaccination in Siguiri Prefecture was 31%. In 2014, the official national OPV3 routine coverage in Guinea was 42%.

All 13 VDPV isolates showed discordant intratypic differentiation results and were further characterized by sequencing the VP1 capsid-coding region. All isolates diverged > 0.6% from the type 2 OPV strain, and classified as type 2 VDPVs. The 13 strains clustered in a monophyletic group with a high (96%) bootstrap value.

Deviation of public health resources to the Ebola outbreak disrupted polio vaccination programs and surveillance activities, which fueled the spread of neurovirulent VDPVs in an area of low vaccination coverage and immunity. Genetic properties of cVDPVs were consistent with their capacity to cause paralytic disease in humans and capacity for sustained person-to-person transmission. Circulation ceased when coverage of oral polio vaccine increased.

A polio outbreak in the context of the Ebola virus disease outbreak highlights the need to consider risks for polio emergence and spread during complex emergencies and urges awareness of the challenges in polio surveillance, vaccination, and diagnosis.